Is the Nufarm share price in the buy zone?

The Nufarm Limited (ASX: NUF) share price has had a tumultuous start to 2019. Is it a buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nufarm Limited (ASX: NUF) share price has had a tumultuous start to 2019. After a slight rally, the company's share price was slashed more than 20% following the release of its half-year results.

However, the relentless selling may be overdone, presenting a decent buying opportunity.

Disappointing results

Seed and crop protection company Nufarm reported its half-year results for the period ending January 2019 last week and the market was not impressed. Nearly $500 million was slashed from the value of the company as Nufarm's share price plummeted almost 23%.

Highlights of the report included an 8% increase in revenue to $1.58 billion, however the company recorded a $13.6 million loss for the first half. Underlying EBITDA was down 2% to $121 million and the interim dividend suspended. Net debt rose from $981 million to $1.58 billion, raising concerns that Nufarm would require a round of capital raising.

The effects of drought

The lack of winter rain was cited by Nufarm in mid-2018, as the company downgraded its earnings guidance twice. The extremely dry conditions affected crop and livestock production, reducing the demand for crop protection and causing an oversupply and reduction in profit margins. As a result, Nufarm announced that production at two formulation plants in Melbourne would be cut back.

Omega 3 Potential

To combat the cyclical nature of crop production and protection, Nufarm is investing heavily in R&D. In partnership with the CSIRO, Nufarm's subsidiary Nuseed is developing and commercialising omega-3 derived from canola. The omega-3 produced from canola has been shown to achieve the same levels of docosahexaenoic acid (DHA) as regular fish oil.

Omega-3 and DHA are important components of many products popular in China, in particular milk and infant formula. The rationale is that as pressure on global fish stocks increases, demand for alternative sources for omega-3 and DHA will increase.

Foolish takeaway

In my opinion, the sell-off in the Nufarm share price could be interpreted as an overreaction. The company has a quality portfolio of agricultural products and if the share price continues to drop, Nufarm could become a takeover target. The potential in omega-3 is also very intriguing, however, I would wait until FDA accreditation is received. Goldman Sachs sees great potential in Nufarm and has issued a buy rating on the company with a price target of $6.00.

Should you invest $1,000 in Mesoblast Limited right now?

Before you buy Mesoblast Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Rising gold share price represented by a green arrow on piles of gold block.
Gold

3 reasons to buy this surging ASX All Ords gold stock today

The ASX All Ords gold stock has doubled investors’ money in 12 months, and this leading expert forecasts more outperformance…

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Broker Notes

Broker reveals outlook for ASX dividend shares amid volatile market

Peter Gardner from Plato Investment Management tells ASX investors where to look for dividend income this year.

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Share Gainers

Why Generation Development, Orica, Pro Medicus, and Zip shares are storming higher today

These shares are having a strong session on Thursday. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why ANZ, Brainchip, Light & Wonder, and Pilbara Minerals shares are falling today

These shares are tumbling on Thursday. But why?

Read more »

A picture of the US Federal Reserve podium for making media announcements.
Share Market News

Why the Fed just left interest rates on hold and what ASX investors can expect next

With the Fed keeping interest rates on hold, when can ASX investors expect the central bank’s next cut?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

A railway worker walks along the train tracks in a visi vest and speaking into a walkie talkie.
Share Market News

Are Aurizon shares a buy, hold or sell based on Macquarie's report?

Here’s what this broker has to say about this Industrials stock

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Leading broker puts buy rating on Zip shares

Big returns could be on offer for investors according to its analysts.

Read more »